Chokepoints After Davos: What Great-Power Politics Now Means for Real Supply Chains

Chokepoints After Davos: What Great-Power Politics Now Means for Real Supply Chains

In this episode, I follow up on Davos 2026 by shifting from speeches and symbolism to the physical realities of global supply chains. The focus is on chokepoints: the Red Sea, Suez, Hormuz, and Taiwan, and on what happens when great-power politics starts to narrow the corridors, systems, and dependencies that modern industries rely on. I look at how recent developments have moved from rhetoric into operating conditions: fragile reopenings, renewed disruptions, and rising uncertainty around routes, energy, shipping, and trade policy. From a pharma and healthcare perspective, the key point is that even when medicines are not shipped directly through a disrupted chokepoint, the upstream systems they depend on still are, whether through energy-intensive inputs, chemical feedstocks, freight capacity, or supplier stability. This episode is about how leaders should think about chokepoints not as distant geopolitical stories, but as very real constraints on cost, replenishment reliability, and network resilience. If you work in supply chain, risk, or executive decision-making, this is an invitation to identify where your system narrows, and what levers you still control before the next disruption hits.

After Davos: Great-Power Theater, Middle-Power Strategy, and Pharma Supply Chains

In this episode, I look at Davos 2026 not as a media show, but as a live stress test of the global order. From Merz’ “age of great powers” narrative to Trump’s tariff threats, Greenland remarks, and pressure over U.S. bonds, Davos made one thing clear: the world is being run more openly as a great-power game again, and middle powers, especially in Europe, are caught in the squeeze. I translate this into the language of pharma and healthcare supply chains. We explore how tariffs, sanctions, export controls, dollar dependence, and critical infrastructure decisions (plants, APIs, IT, banks) create structural exposure for your network. Using examples from pharma, automotive, and banking, I show how the same pattern repeats across industries: highly regulated, high-stakes systems built on a few geopolitical chokepoints. Finally, I outline what a “middle-power supply chain strategy” could look like in practice: rethinking your exposure map, identifying a few structural dependencies you can actually change, and giving geopolitical risk a real home in your governance. If you’re responsible for supply chain, risk, or corporate strategy in a BANI world, this episode is an invitation to move beyond headline reactions and start managing a deliberate great-power risk portfolio. Connect with me on LinkedIn: Ralph Leyendecker | LinkedIn [https://www.linkedin.com/in/ralphleyendecker/]

From Country Crisis to Risk Portfolio – How Pharma Supply Chains should think about Geopolitics

In this episode, I move beyond “one crisis at a time” and look at geopolitics through the lens of a risk portfolio for pharma and med-tech supply chains. Starting from recent events like Venezuela, the Red Sea, Taiwan, and Europe’s energy debate, I sketch a simple way to map exposure versus geopolitical fragility – not as a theoretical exercise, but as a practical tool for network and governance decisions. I talk about what leaders can actually control: where buffers sit, how contracts handle sanctions and export controls, how decision rights are set, and which trade lanes are treated as “single points of failure.” Using a concrete Latin America scenario, I walk through how a portfolio mindset changes the way you react to shocks, design options, and explain trade-offs to boards and regulators. If you’re responsible for supply chain, risk, or governance in a BANI world, this episode is an invitation to make your geopolitical exposure visible, link it to real levers you can set, and move from reactive crisis management to deliberate portfolio thinking.

Venezuela and the BANI World – Implications for Health and Pharma Supply Chains

In this episode, I unpack the recent U.S. military operation that led to Nicolás Maduro’s capture and ongoing narco-terrorism proceedings in New York, and look at what this actually means for health and pharma supply chains in and around Venezuela. Rather than debating the politics, I focus on access to medicines, sanctions and logistics friction, and two working scenarios: a managed transition with selective relief versus a prolonged standoff where Venezuela remains a high-friction, low-priority market. I also explore how spillover effects, migration, shifting demand, and NGO procurement, could impact neighboring health systems. Finally, I translate this into practical actions for pharma and med-tech leaders: mapping exposure, separating humanitarian and commercial channels, tightening sanctions and compliance processes, building regional flexibility, and watching operational indicators instead of just political headlines, all framed through a BANI lens.

Holiday Message – Merry Christmas and see you in 2026!

This short holiday episode is a quick thank-you from me to you before I step away for a year-end break. I share a few reflections on this past year in pharma supply chains and what’s coming next for the podcast, then hit pause until the new year. Wishing you a Merry Christmas, and a healthy start into the new year. See you soon in the next season of Supply Chain 360.